Abstract
Mitoxantrone at a dose of 15 mg/m2 i.v. q 3 weeks failed to produce responses in 29 adequately treated patients with measurable advanced renal cell carcinoma. The side-effects observed in this group of patients with a good performance status were generally mild. On the basis of this negative result, the application of mitoxantrone in this disease is not recommended.
MeSH terms
-
Adult
-
Aged
-
Anthraquinones / adverse effects
-
Anthraquinones / therapeutic use*
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use*
-
Carcinoma, Renal Cell / drug therapy*
-
Drug Evaluation
-
Female
-
Humans
-
Kidney Neoplasms / drug therapy*
-
Male
-
Middle Aged
-
Mitoxantrone
Substances
-
Anthraquinones
-
Antineoplastic Agents
-
Mitoxantrone